obesity drug news today glp-1 2025 sep 30 Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society The next phase of the

Description

& Klein, J

Other studies have also noted thyroid hormone changes in people with obesity who were treated with semaglutide

Analysis of Obesity GLP-1 Market by Key Country The obesity GLP-1 market is growing rapidly across major economies, with China and the United States both recording 25.4% CAGR through 2035, driven by large treatment-eligible populations and expanding access frameworks

Budy is not a medical provider and does not replace medical advice

Call your health care provider if you have any of the following symptoms: pain in your upper stomach (abdomen), fever, yellowing of your skin or eyes (jaundice), or clay-colored stools Increased risk of low blood sugar (hypoglycemia) in adults with type 2 diabetes who also take medicines to treat type 2 diabetes such as sulfonylureas or insulin Signs and symptoms of low blood sugar may include: shakiness, sweating, headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, fast heartbeat, and feeling jittery